Contact Sessions
James Skelley | Technology Lawyer
SESSIONS
Sessions are online meetups for discussing recent legal news, general education, and sharing various of James' research. The next scheduled session is:


You can find a complete listing of upcoming sessions and request to join HERE.
(Informal 1-2 line summaries, which certainly should not be relied upon for legal or other research purposes)
RECENT CASE HIGHLIGHTS
    • CAFC denies this writ of mandamus to reconsider the Board's denial for IPR institution based on the "settled expectations" of the patents' age. Salient, in view of the recently proposed change in IPR rules and institution, however, is dicta regarding challenges:
      Congress committed institution decisions to the Director’s discretion . . . and protected exercise of that discretion from judicial review by making such determinations “final and nonappealable,” 35 U.S.C. § 314(d), mandamus is ordinarily unavailable for review of institution decisions . . . That general prohibition bars review of decisions denying institution of IPR proceedings for efficiency reasons based on parallel district court litigation involving the same patents . . . Cambridge’s constitutional challenges . . . fail to identify the kind of property rights or retroactivity concerns that might give rise to a colorable Due Process Clause claim . . . Cambridge’s expectation that the PTO would evaluate its petition based on only certain criteria, moreover, is insufficient to establish a constitutional due process violation . . . We reiterate that we do not decide whether the PTO’s actions are correct or whether the use of this factor is permitted under the statutes. Nor do we address the availability of mandamus relief for other challenges to institution decisions based on non-constitutional grounds. We decide only that Cambridge has failed to show a clear and indisputable right to the relief requested given the limits on our review of the PTO’s decision to deny institution.
    • In this precedential decision, CAFC affirms the no trade secrets JMOL and no inventorship correction decisions below. Regarding the JMOL, the DCT found:
      (1) TS 7, TS 11, TS 20, and TS 24 are not sufficiently definite; (2) TS 11, TS 20, TS 23, and TS 24 are not “secret;” (3) TS 7, TS 11, TS 20, and TS 23 had never been used or disclosed by Goodyear; and (4) TS 11 and TS 20 were never conveyed by Coda to Goodyear.
      CAFC applies the Ohio trade secret statute to arrive at the same conclusions ("We conclude that the district court correctly determined that (1) Coda publicly disclosed the information covered by TS 24, and (2) to the extent that TS 24 covered knowledge not disclosed in Coda’s publications, Coda failed to identify TS 24 with sufficient particularity."). For example, "Coda’s knowledge regarding the optimal location for placement of a pump in a tire" appeared publicly in a PCT application and was visible on the tire itself. Trying to overcome this conclusion "Coda asserts that the 2007 PCT application and the 2008 Tire Technology article do not disclose a pump that was “part of a conventional tire sidewall”", but this then runs into the definiteness issue ("We reject Coda’s attempt to belatedly introduce additional specificity into the trade secret based on Mr. Hrabal’s trial testimony and attorney argument."). Other of the alleged trade secrets likewise encounter definiteness issues ("[T]he listed functions are described in vague terms with no detail regarding how those functions are carried out") as well as use issues ("[T]he only alleged evidence of use presented by Coda was a January 21, 2009 email that did not contain the test results described in TS 23"). CAFC concludes by agreeing with the denial to correct inventorship, since the associated arguments were predicated upon the trade secrets ("Coda’s challenges to the district court’s judgments regarding the correction of inventorship and trade secret claims rise and fall together because Coda’s sole argument supporting reversal of the district court’s denial of correction of inventorship is that the district court improperly granted judgment as a matter of law with respect to Coda’s trade secret claims").
    • CAFC briefly affirms IPR obviousness invalidity for patents relating "to systems for generating code to provide content on a display of a device."
      "Meta relied on prior art combinations that used a Java Virtual Machine (“JVM”) to satisfy the “player” limitation . . . Express Mobile’s theory is that an ordinarily skilled artisan would not conclude that the JVM provides instructions “because it causes a different component—the servlet—to generate a webpage, which causes yet another component—the web server—to provide the webpage to the browser” . . . The Board agreed with Meta that “nothing in the challenged claims requires that the Player itself directly present or physically draw the user interface for the user; the claim requires only that the Player provide ‘instructions’ for such display” . . . These factual findings are supported by substantial evidence."
    • A brief, but precedential, ITC case, wherein CAFC reverses since the Board's classification of the good as a "diary" rather than a "calendar" conflicts with precedent. Basically, CAFC previously held that "[a] diary is retrospective, not prospective . . . The Trade Court thus erred by expansively interpreting “diary” to include “prospective scheduling devices,” and accordingly misclassified Blue Sky’s planner as a “diary” under subheading 4820.10.20.10." Ergo, reversed and remanded to reconsider the government's position.
    • In this precedential opinion, CAFC reverses the failure to grant JMOL for lack of written description and enablement on claims concerning "a type of cancer treatment known as an antibody-drug conjugate (“ADC”)." Basically, after the priority filing, a competitor prepared a competing structure, which continuation claims were (seemingly) tortured to read upon ("One cannot avoid the suspicion that the ’039 patent was filed specifically to encompass Enhertu, which of course is permissible if it was entitled to a filing date antedating any public disclosure of Enhertu."). Here, CAFC doesn't see substantial evidence for the jury's written description determination:
      The 2004 application only broadly outlines the possible structures of the Ww peptide unit that are included in the linker protein . . . a patent’s disclosure of a “broad genus,” without more, is inadequate to satisfy the written description requirement for claims directed to a “particular subgenus or species contained therein.”
      CAFC likewise finds enablement lacking for similar reasons ("[J]ust as in Amgen, a skilled artisan would be left to perform far-ranging “trial-and-error discovery” to make and use the ADCs within the scope of the ’039 patent."). Ergo, reversed.
More . . .
ABOUT
James Skelley is a solo practitioner based in Mountain View, California since 2015, focusing primarily upon technology transactions and intellectual property procurement. James' practice also serves as an "incubator" for new legal service technologies / methodologies and a "living example" of their application. To this end, James regularly partners with larger law firms and with his clients so as to improve the practice of intellectual property law.

LEGAL PRACTICE AREAS
  • Utility / Design / PCT Patent Prosecution
  • Open Source Diligence
  • Technology Transactions (typically as a team)
  • Litigation / Inter Partes Review Support (typically as a team)
  • James tends NOT to handle low-volume trademark work (though referrals are available)
LICENSING
  • USPTO - #59458 - 10/16/2006
  • California - #257829 - 12/01/2008
  • District Columbia - #1014986 - 08/05/2013
CONTACT
  • James is available by email, 8x8 hangout, and in-person meetups in the Valley.
  • Email is typically the best way to reach James.
TECHNICAL FIELDS
  • Machine Learning / Robotics
  • Cryptograpy / Cryptocurrency / Smart Contracts
  • Medical Device
  • Computational Biology (primarily modeling and proteomics)
  • Signal Processing (primarily wireless and compression)
  • Quantum Physics (primarily semiconductor) / Electromagnetics (antennae, waveguides, etc.)
  • Manufacturing / 3D Printing
  • James tends NOT to handle pure chemistry applications (though referrals are available), however James HAS handled matters involving computational proteomics, cellular modeling, and diagnostic lab protocols
SOFTWARE
LAWMUX BITES
LawMux Bites are (very) short, one-page summaries of various legal concepts, cases, and technologies. As informal summaries, you certainly shouldn't rely upon them as legal advice / for business use, but they can help orient you if you're new to the subject matter.

LAWMUX BITES
SHORT, INFORMAL NOTES
Similar to LawMux Bites, notes are (very) short writeups calling attention to various issues. As informal summaries, you certainly shouldn't rely upon them as legal advice / for business use, but they can help orient you to the relevant topic.

PAPERS / ARTICLES